Generation Bio Welcomes Steven Dowdy, Ph.D., to its Scientific Advisory Board
CAMBRIDGE, Mass., Oct. 29, 2019 – Generation Bio, a company working to expand the reach of gene therapy through a novel construct and targeted delivery, today announced that Steven Dowdy, Ph.D., a distinguished expert in cellular and molecular medicine, has joined its Scientific Advisory Board.
“Steve brings decades of expertise and an unbridled enthusiasm for the fields of genetics and molecular medicine,” said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. “He specializes in the development and delivery of novel therapies for genetic disorders and his insights will undoubtedly prove valuable as we advance toward the clinic with multiple therapeutic candidates for liver disorders. We are pleased to welcome him to our Scientific Advisory Board.”
Dr. Dowdy is a professor of cellular and molecular medicine at the University of California San Diego School of Medicine, where his research has focused on the delivery of novel therapeutics, especially RNAi therapies, into cells. He previously served as an investigator at the Howard Hughes Medical Institute and an assistant professor of pathology and medicine at the Washington University School of Medicine in St. Louis. In addition to Generation Bio, he serves on the Scientific Advisory Boards of Deep Genomics and NeuBase Therapeutics and is a member of the Board of Directors of the Oligonucleotide Therapeutics Society. He is a coauthor of more than 100 peer-reviewed publications in cell and molecular medicine. Dr. Dowdy earned his Ph.D. in microbiology and molecular genetics at the University of California School of Medicine and holds a B.S. with honors from the School of Biological Sciences at the University of California Irvine. He conducted postdoctoral research with Dr. Robert Weinberg at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology.
“Generation Bio’s advances in developing a novel non-viral construct and targeted delivery approach are truly impressive. Their platform has the potential to disrupt the paradigm of gene therapies and bring these transformative treatments to patient populations on a much larger scale than has previously been envisioned,” Dr. Dowdy said. “I look forward to offering guidance and support to Generation Bio’s world-class team as they lead gene therapy into a new future.”
About Generation Bio
Generation Bio is a biotechnology company working to extend the benefits of gene therapy to more families, living with a broader range of diseases, around the world. The company is harnessing its proprietary ceDNA construct, coupled with a proven lipid nanoparticle delivery system, to enable the development of therapies with durable gene expression and the ability to re-dose, titrate and manufacture on a global scale. Generation Bio is advancing a diverse portfolio of programs for diseases of the liver, and is also developing delivery systems for additional tissues, including the eye, muscle and brain. Generation Bio was founded and launched by Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.generationbio.com or follow @generationbio.
Ten Bridge Communications